JILLIAN ADAMS: Open Payments
NPI 1033513031 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,467 in 65 payments from 12 companies in 2025. Trend: 2023 $2,851 · 2024 $3,101 · 2025 $2,467
Food & beverage: $2,467
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $444 |
| Axsome Therapeutics, Inc. | 12 | $368 |
| Alkermes, Inc. | 10 | $326 |
| Otsuka America Pharmaceutical, Inc. | 6 | $259 |
| E.R. Squibb & Sons, L.L.C. | 3 | $226 |
| Collegium Pharmaceutical, Inc. | 2 | $214 |
| ABBVIE INC. | 12 | $185 |
| Lundbeck LLC | 7 | $174 |
| Vanda Pharmaceuticals Inc. | 1 | $117 |
| Tris Pharma Inc | 1 | $115 |
Products named: CAPLYTA, REXULTI, Auvelity, LYBALVI, COBENFY, Jornay PM, VRAYLAR, FANAPT.
Industry payments across TX — which companies pay providers there.
